IP Library Granted Patent US 10,028,945
Granted Patent B2
US 10,028,945 · App. 15/285,818 · Granted Jul 24, 2018

Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof

Inventors: Thomas E. Jenkins (Half Moon Bay, CA); Craig O. Husfeld (San Mateo, CA); Julie D. Seroogy (San Carlos, CA); Jonathan W. Wray (San Francisco, CA)
Assignee: Signature Therapeutics, Inc.
A61K31/485A61K31/445A61K31/495A61K38/05A61K47/48023A61K47/48038
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,028,945
App. No.
15/285,818
Granted
Jul 24, 2018
Kind
B2
Abstract

A method of providing a patient with controlled release of ketone-containing opioid using a prodrug capable, upon enzymatic activation and intramolecular cyclization, of releasing the ketone-containing opioid is disclosed. The disclosure also provides such prodrug compounds and pharmaceutical compositions comprising such compounds. Such pharmaceutical compositions can optionally include an enzyme inhibitor that interacts with the enzyme(s) to mediate the enzymatically-controlled release of the ketone-containing opioid from the prodrug so as to modify enzymatic cleavage of the prodrug. Also included are methods to use such compounds and pharmaceutical compositions.

Claims (54)

1. A composition comprising:

(i) a trypsin inhibitor; and

(ii) a compound of formula KC-(IIIa):

wherein:

X represents a residue of a ketone-containing opioid, wherein the hydrogen atom of the corresponding enolic group of the ketone is replaced by a covalent bond to —C(O)—NR 5 —(C(R 1 )(R 2 )) n —NR 3 R 4 ;

R 5 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;

each R 1 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;

each R 2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;

or R 1 and R 2 together with the carbon to which they are attached form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group, or two R 1 and R 2 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group;

n is an integer from 2 to 4;

R 3 is hydrogen;

R 4 is

each R 6 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl, or optionally, R 6 and R 7 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;

each W is independently —NR 8 —, —O— or —S—;

each R 8 is independently selected from hydrogen, alkyl, substituted alkyl, aryl and substituted aryl, or optionally, each R 6 and R 8 independently together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;

p is an integer from one to 100; and

R 7 is selected from hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, and substituted arylalkyl;

or a salt, hydrate or solvate thereof; or

(i) a trypsin inhibitor; and

(ii) a compound of formula KC-(IIIb):

wherein:

X represents a residue of a ketone-containing opioid, wherein the hydrogen atom of the corresponding enolic group of the ketone is replaced by a covalent bond to —C(O)—NR 5 —(C(R 1 )(R 2 )) n —NR 3 R 4 ;

R 5 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;

each R 1 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;

each R 2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;

or R 1 and R 2 together with the carbon to which they are attached form a cycloalkyl or substituted cycloalkyl group, or two R 1 or R 2 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl or substituted cycloalkyl group;

n is an integer from 2 to 4;

R 3 is hydrogen;

R 4 is

each R 6 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl, or optionally, R 6 and R 7 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;

each W is independently —NR 8 —, —O— or —S—;

each R 8 is independently selected from hydrogen, alkyl, substituted alkyl, aryl and substituted aryl, or optionally, each R 6 and R 8 independently together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;

p is an integer from one to 100; and

R 7 is selected from hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, and substituted arylalkyl;

or a salt, hydrate or solvate thereof.

2. The composition of claim 1 , wherein the ketone-containing opioid is selected from acetylmorphine, hydrocodone, hydromorphone, ketobemidone, methadone, naloxone, N-methylnaloxone, naltrexone, N-methylnaltrexone, oxycodone, oxymorphone, and pentamorphine.

3. The composition of claim 1 , wherein the ketone-containing opioid is hydrocodone or oxycodone.

4. The composition of claim 1 , wherein R 5 is (1-4C)alkyl.

5. The composition of claim 4 , wherein R 5 is methyl or ethyl.

6. The composition of claim 1 , wherein R 1 and R 2 are hydrogen.

7. The composition of claim 1 , wherein R 1 and R 2 which are on the same carbon are methyl.

8. The composition of claim 1 , wherein one of R 1 and R 2 is aminoacyl.

9. The composition of claim 1 , wherein one of R 1 and R 2 is —C(O)NR 10a R 10b , wherein each R 10a and R 10b is independently selected from hydrogen, alkyl, substituted alkyl, and acyl.

10. The composition of claim 1 , wherein one of R 1 and R 2 is —C(O)NR 10a R 10b , wherein R 10a is an alkyl and R 10b is substituted alkyl.

11. The composition of claim 1 , wherein n is 2 or 3.

12. The composition of claim 1 , wherein R 4 is a residue of an L-amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glycine, glutamine, glutamic acid, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine, or a residue of an N-acyl derivative of any of said amino acids; or a residue of a peptide composed of at least two L-amino acid residues selected independently from alanine, arginine, asparagine, aspartic acid, cysteine, glycine, glutamine, glutamic acid, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine or a residue of an N-acyl derivative thereof.

13. The composition of claim 12 , wherein the N-acyl derivative is an acetyl, benzoyl, malonyl, piperonyl or succinyl derivative.

14. The composition of claim 1 , wherein R 4 is a residue of L-arginine or L-lysine, or a residue of an N-acyl derivative of L-arginine or L-lysine.

15. The composition of claim 1 , wherein R 6 is a side chain of an amino acid.

16. The composition of claim 1 , wherein R 6 is —H, —CH 2 CH 2 CH 2 NH(C═NH)NH 2 or —CH 2 CH 2 CH 2 CH 2 NH 2 .

17. The composition of claim 1 , wherein R 7 is selected from hydrogen, acetyl, benzoyl, malonyl, piperonyl and succinyl.

18. The composition of claim 1 , wherein the compound is selected from the following formulae:

19. The composition of claim 1 , wherein the trypsin inhibitor is an arginine mimic or a lysine mimic.

20. A method of treating or preventing pain comprising administering an effective amount of a composition of claim 1 to a patient in need thereof.

Assignments (6)
SECURITY INTEREST Recorded Dec 18, 2023
From: ENSYSCE BIOSCIENCES, INC.; EBI OPCO, INC.; EBI OPERATING, INC.; EBIR, INC.
To: 3I, LP
Reel/Frame 065902/0035 →
SECURITY INTEREST Recorded Nov 14, 2023
From: ENCSYSCE BIOSCIENCES, INC.
To: 3I, LP
Reel/Frame 065553/0389 →
SECURITY INTEREST Recorded Jul 8, 2022
From: ENSYSCE BIOSCIENCES, INC.; EBI OPCO, INC.; EBI OPERATING, INC.; COVISTAT, INC.
To: 3I, LP
Reel/Frame 060616/0487 →
SECURITY INTEREST Recorded Oct 4, 2021
From: ENSYSCE BIOSCIENCES, INC.
To: 3I, LP
Reel/Frame 057785/0054 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2017
From: JENKINS, THOMAS E.; HUSFELD, CRAIG O.; SEROOGY, JULIE D.; WRAY, JONATHAN W.
To: PHARMACOFORE, INC.
Reel/Frame 041112/0182 →
CHANGE OF NAME Recorded Jan 27, 2017
From: PHARMACOFORE, INC.
To: SIGNATURE THERAPEUTICS, INC.
Reel/Frame 041541/0166 →
Continuity (4)
Continuation 13393470
Provisional Application 61240611 · Sep 8, 2009
Provisional Application 61288148 · Dec 18, 2009
Related Publication 20170119754A1 · May 4, 2017